Additional file 6: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
- Resource Type
- Authors
- Narendra Bharathy; Berlow, Noah; Wang, Eric; Jinu Abraham; Settelmeyer, Teagan; Hooper, Jody; Svalina, Matthew; Bajwa, Zia; Goros, Martin; Hernandez, Brian; Wolff, Johannes; Ranadip Pal; Davies, Angela; Arya Ashok; Bushby, Darnell; Mancini, Maria; Noakes, Christopher; Goodwin, Neal; Ordentlich, Peter; Keck, James; Hawkins, Douglas; Rudzinski, Erin; Atiya Mansoor; Perkins, Theodore; Vakoc, Christopher; Michalek, Joel; Keller, Charles
- Source
- Subject
- 3. Good health
- Language
Table S1. Treatment schedule for PDX models. Table S2. Patient history of PDX eRMS models. Table S3. Statistical summary for CTG-1213/POS-13212. Table S4. Statistical summary for CTG1116/POS-13166. Table S5. Statistical summary for CTG-1628/POS-132166B. Table S6. Statistical summary for J0103366/CF-13A. Table S7. Histological markers of differentiation in PDX eRMS (CTG-1213) mice. Table S8. Patient history of PDX pleoRMS models. Table S9. Statistical summary for CTG-1213/POS-13212. Table S10. Statistical summary for CTG1116/POS-13166. Table S11. Statistical summary for CTG-1628/POS-132166B. Table S12. Histological markers of differentiation in PDX pleoRMS (CTG-800) mice. Table S13. Primers for RT-PCR. (DOCX 41 kb)